Author(s): Veronika Sexl, Edit Porpaczy, Sabrina Tripolt, et al. Abstract: S130 Session topic: 16. Myeloproliferative neoplasms – Clinical Background Inhibition of Janus-kinase 1/2 (JAK1/2) is a mainstay to treat myeloproliferative neoplasms (MPN). Besides driving MPN, the JAK-STAT pathway is involved in the development of malignant lymphoma. Recent reports point towards a slightly increased risk...
Pro zobrazení tohoto obsahu je třeba být přihlášen.